• Microbix Biosystems (TSX:MBX) has signed an agreement with R-Biopharm AG to distribute its Quality Assessment Products (QAPs)
  • Under the agreement, R-Biopharm will distribute the QAPs to 11 countries throughout Australasia, Europe and North America
  • R-Biopharm will also provide marketing, sales and logistical support
  • The agreement pertains to Microbix’s QAPs for sexually-transmitted, respiratory and gastrointestinal infections
  • Microbix Biosystems (MBX) is currently up 1.47 per cent and is trading at C$0.34 per share, with a market cap of $37.52 million

Microbix Biosystems (TSX:MBX) has signed an agreement with R-Biopharm AG to distribute its Quality Assessment Products (QAPs).

There are currently four-dozen QAPs across Microbix’s PROCEEDx and REDx Controls tradenames, which aim to increase the accuracy of bacterial and viral diseases tests. The QAPs span sexually-transmitted, gastrointestinal and respiratory infections, including SARS-CoV-2, which causes COVID-19.

Under the terms of the agreement, R-Biopharm will distribute the products to Australia, Belgium, Canada, France, Germany, Luxembourg, the Netherlands, New Zealand, Norway, Spain and the United Kingdom.

R-Biopharm will, in addition to the supply of the products, oversee the necessary marketing, sales, technical support and logistical requirements relating to the QAPs. The Darmstadt, Germany-based company already has existing relationships with a range of clinical labs.

Phil Casselli, Senior Vice President of Sales and Business Development at Microbix, said that he is very pleased to have secured R-Biopharm as a distribution partner.

“As a globally recognized diagnostic test manufacturer, they regularly meet with key personnel in hospitals and clinical labs.

“Our controls are a perfect complement to their product mix and their field team is well suited to deliver excellent user-training and after sales support for our growing PROCEEDx and REDx Controls product lines,” he said.

Meanwhile, Andreas Simons, Director of Product Management, Clinical Diagnostics, at R-Biopharm, also commented on the agreement, noting the ever-increasing need to improve the accuracy of clinical diagnostic testing.

“We’re pleased to secure access to Microbix’s innovative QAPs for sexually-transmitted, respiratory, and gastrointestinal infections as a complementary portfolio for our laboratory customers,” he said. 

Microbix Biosystems (MBX) is currently up 1.47 per cent and is trading for C$0.34 per share at 12:48pm EDT.

More From The Market Online

Theralase adds cancer immunotherapy to potential revenue streams

Theralase Technologies' (TSXV:TLT) lead drug candidate, Rutherrin, enhanced cancer immunotherapy in a pre-clinical setting.

Revolutionizing medical imaging with nanocarbon-based contrast drugs

The partnership between Rain Cage Carbon and Voyageur Pharmaceuticals (TSXV:VM) is transforming carbon capture and reuse technology.

Optimi Health completes first MDMA shipment to Israel

Optimi Health (CSE:OPTI) recently touted several milestones it had achieved in its international psychedelic supply operations strategy.

Theralase enhances cancer drug efficacy

Theralase Technologies (TSXV:TLT) announces its Ruvidar compound creates a new compound able to significantly kill more cancer cells.